US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

265.54

-5.3900-1.99%

Volume:48.43K

Turnover:12.85M

Market Cap:2.91B

PE:31.07

High:272.86

Open:272.86

Low:262.35

Close:270.93

52wk High:275.23

52wk Low:182.08

Shares:10.95M

Float Shares:10.95M

Volume Ratio:1.27

T/O Rate:0.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.04

PE(LYR):7.03

Loading ...

Overview Company News Filings

Positive Report for Neo Performance Materials Inc (NEO) from Jefferies

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Alkermes (ALKS) Gets a Hold from Goldman Sachs

Corcept Therapeutics Announces New Endocrinology Division President

Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires

Corcept Announces Planned Leadership Transition

THOMSON REUTERS

Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II

Veracyte Global Chief Commercial Officer John Leite Sells 4,015 Shares for $160,600

Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says

MT Newswires Live

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD)

Alkermes Plc : Jefferies Raises Target Price to $83 from $78

THOMSON REUTERS

Alkermes data show measurable improvements in ADHD, says H.C. Wainwright

Alkermes Price Target Maintained with a $62.00/Share by Needham

Alkermes Plc : Baird Raises Target Price to $61 from $58

THOMSON REUTERS

Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell

MT Newswires Live

U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes

Alkermes jumps 8% to $46.99 after Phase I adult ADHD data

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/FBT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":265.54,"timestamp":1791306626516,"preClose":270.93,"halted":0,"volume":48430,"delay":0,"changeRate":-0.019894437677628857,"floatShares":10950002,"shares":10950002,"eps":8.545272,"marketStatus":"Trading","change":-5.39,"latestTime":"10-06 13:10:52 EDT","open":272.855,"high":272.855,"low":262.35,"amount":12847465.844400002,"amplitude":0.038774,"askPrice":265.49,"askSize":117,"bidPrice":265.29,"bidSize":104,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791316800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":270.93,"sharesOutstanding":11450002,"nav":266.33,"aum":2902997532.66,"bidAskSpread":0.000914,"preHourTrading":{"tag":"盘前","latestPrice":270.93,"preClose":270.93,"latestTime":"08:11 EDT","volume":4,"amount":1082.099,"timestamp":1791288685408,"change":0,"changeRate":0,"amplitude":0.007238},"postHourTrading":{"tag":"盘后","latestPrice":270.93,"preClose":270.93,"latestTime":"19:30 EDT","volume":18,"amount":4873.78,"timestamp":1791243000792,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2653,"impliedVol":0.2501,"impliedVolPercentile":0.9203},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10950002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":1.2653,"shares":10950002,"dividePrice":0,"high":272.855,"amplitude":0.038774,"preClose":270.93,"low":262.35,"week52Low":182.08,"pbRate":"1.04","psRate":"701.44","week52High":275.23,"institutionHeld":0,"latestPrice":265.54,"committee":-0.058824,"eps":8.545272,"divideRate":0,"volume":48430,"delay":0,"ttmEps":8.545272,"open":272.855,"prevYearClose":206.52,"prevWeekClose":266.44,"prevMonthClose":272.26,"prevQuarterClose":272.26,"fiveDayClose":272.58,"twentyDayClose":265.78,"sixtyDayClose":247.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670347159","title":"Positive Report for Neo Performance Materials Inc (NEO) from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2670347159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670347159?lang=en_us&edition=fundamental","pubTime":"2026-09-26 20:15","pubTimestamp":1790424943,"startTime":"0","endTime":"0","summary":"Neo Performance Materials Inc received a Buy rating and price target from Jefferies analyst Laurence Alexander yesterday. The company’s shares clos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-report-for-neo-performance-materials-inc-neo-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-report-for-neo-performance-materials-inc-neo-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106261612.USD","LU0012050646.USD","FBT","NEO","UYM","BK4196","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670427886","title":"Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2670427886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670427886?lang=en_us&edition=fundamental","pubTime":"2026-09-26 05:12","pubTimestamp":1790370720,"startTime":"0","endTime":"0","summary":"Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment intensificatio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/25/3369344/0/en/veracyte-announces-eight-decipher-focused-studies-to-be-presented-at-astro-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4165","BK4192","GRID","ADT","VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669460339","title":"Alkermes (ALKS) Gets a Hold from Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669460339","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669460339?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:45","pubTimestamp":1790250329,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Andrea Newkirk resumed coverage with a Hold rating on Alkermes today and set a price target of $50.00. According to TipRanks,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alkermes-alks-gets-a-hold-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alkermes-alks-gets-a-hold-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1868837300.USD","LU0251131958.USD","LU2471134796.USD","LU0868494617.USD","IBRN","LU2237443622.USD","LU0868494708.USD","LU1804176565.USD","BK4504","BK4585","LU1868836591.USD","LU2471134523.USD","LU2237443465.HKD","LU1868836757.USD","IE0034235188.USD","LU1668664300.SGD","GSX","MEDX","LU2265009873.SGD","BK4588","IE00B19Z3B42.SGD","FBT","IE0004091025.USD","BK4533","LU1791807156.HKD","PSIL","IE0002270589.USD","LU1144417596.USD","LU0742534661.SGD","ALKS","LU1894683348.USD","LU2237443978.SGD","PSCH","LU2896262040.SGD","BK4516","BK4552","LU2471134879.HKD","BK4550","LU0345770308.USD","LU1894683264.USD","LU2237438978.USD","LU1868837136.USD","LU0210536198.USD","IE00BSNM7G36.USD","IE0004086264.USD","LU2237443895.HKD","IE00B19Z3581.USD","LU2471134952.CNY","LU2750360641.GBP","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669448936","title":"Corcept Therapeutics Announces New Endocrinology Division President","url":"https://stock-news.laohu8.com/highlight/detail?id=2669448936","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669448936?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:01","pubTimestamp":1790168500,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics ( ($CORT) ) has shared an announcement. On September 22, 2026, Corcept Therapeutics said Sean Maduck, president of its Endocri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-announces-new-endocrinology-division-president?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/corcept-therapeutics-announces-new-endocrinology-division-president?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1559883803.SGD","BK4532","BK4007","LU0566484027.USD","PSCH","FBT","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669459483","title":"Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires","url":"https://stock-news.laohu8.com/highlight/detail?id=2669459483","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669459483?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:02","pubTimestamp":1790164960,"startTime":"0","endTime":"0","summary":"Corcept names Justin Gunn president of endocrinology as Sean Maduck retiresCorcept named Justin Gunn president of its Endocrinology division, effective Oct. 1, succeeding retiring Sean Maduck.Gunn wil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL6My5bl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","LU1559883803.SGD","CORT","FBT","BK4007","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483929","title":"Corcept Announces Planned Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483929","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483929?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:00","pubTimestamp":1790164803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA7JP7GY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","BK4532","CORT","PSCH","LU0566484027.USD","BK4007","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669108132","title":"Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II","url":"https://stock-news.laohu8.com/highlight/detail?id=2669108132","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669108132?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:24","pubTimestamp":1790144664,"startTime":"0","endTime":"0","summary":"An update from Sensorion SAS ( ($FR:ALSEN) ) is now available. Sensorion has sharpened its strategic focus on SENS-601, a single-vector AAV gene th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sensorion-doubles-down-on-gjb2-gene-therapy-as-sens-601-enters-phase-i-ii?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sensorion-doubles-down-on-gjb2-gene-therapy-as-sens-601-enters-phase-i-ii?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","SENS","IBBQ","BK4082","SYNB","IBB","BK4588","LFSC","GNOM","CNCR","BK4585","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669160127","title":"Veracyte Global Chief Commercial Officer John Leite Sells 4,015 Shares for $160,600","url":"https://stock-news.laohu8.com/highlight/detail?id=2669160127","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669160127?lang=en_us&edition=fundamental","pubTime":"2026-09-23 05:16","pubTimestamp":1790111816,"startTime":"0","endTime":"0","summary":"Veracyte Global Chief Commercial Officer John Leite sells 4,015 shares for $160,600Veracyte Global Chief Commercial Officer John Leite sold 4,015 common shares on Sep. 21, 2026 at $40.Post-transaction","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL6xgDbt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Veracyte Global Chief Commercial Officer John Leite Sells 4,015 Shares for $160,600","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","VCYT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669232251","title":"Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669232251","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669232251?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:39","pubTimestamp":1790091552,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's confidence in ALKS7290 and reinforced the potential of its broader \"orexin pipeline,\" RBC Capital Market","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PSIL","PSCH","MEDX","ABVC","BK4139","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669678146","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669678146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669678146?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:50","pubTimestamp":1790074221,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD). AnaptysBi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-anaptysbio-anab-alkermes-alks-and-iradimed-irmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-anaptysbio-anab-alkermes-alks-and-iradimed-irmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABU","BK4588","LU0029874061.USD","BK4585","LU0128526141.USD","IBRN","XBI","XLV","MEDX","BK4137","FBT","BK4082","BK4581","PSCH","ALKS","ANAB","FFTY","HCSG","PSIL","IRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669611593","title":"Alkermes Plc : Jefferies Raises Target Price to $83 from $78","url":"https://stock-news.laohu8.com/highlight/detail?id=2669611593","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669611593?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:28","pubTimestamp":1790054919,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E03X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","BK4139","PSIL","PSCH","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669167844","title":"Alkermes data show measurable improvements in ADHD, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167844","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167844?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:40","pubTimestamp":1790008814,"startTime":"0","endTime":"0","summary":"H.C. Wainwright keeps a Neutral rating on Alkermes (ALKS) after the company reported the first clinical evidence of an orexin-2 receptor agonist pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-data-show-measurable-improvements-in-adhd-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-data-show-measurable-improvements-in-adhd-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","PSIL","ABVC","ALKS","FBT","PSCH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916926","title":"Alkermes Price Target Maintained with a $62.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916926","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916926?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:11","pubTimestamp":1789999860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALKS/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","PSCH","MEDX","BK4139","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669166716","title":"Alkermes Plc : Baird Raises Target Price to $61 from $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2669166716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669166716?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:33","pubTimestamp":1789997614,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D0EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSCH","FBT","PSIL","MEDX","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669976165","title":"Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669976165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669976165?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:43","pubTimestamp":1789994623,"startTime":"0","endTime":"0","summary":"Alkermes  said Monday its drug candidate ALKS 7290 showed clinically meaningful improvements from baseline on exploratory endpoints in a phase 1b study in patients with attention-deficit hyperactivity disorder or ADHD.The company said it measured improvements using the Adult ADHD Investigator Symptom Rating Scale and Clinical Global Impression-Severity Scale after 14 days of treatment.ALKS 7290 was generally well-tolerated at all doses tested in healthy volunteers and adults with ADHD, the company said. The study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts, it added.The company said it enrolled the first of an expected 312 participants in a phase-2 study this month. The trial will evaluate the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo, with data expected next year.Shares of the company were up over 7% in Monday's premarket activity.Price: 46.50, Change: +3.11, Percent Change: +7.17","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALKS","FBT","ABVC","MEDX","BK4139","PSCH","PSIL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669099168","title":"U.S. Stocks on the MOVE-Accenture, Arhaus, Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2669099168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669099168?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:52","pubTimestamp":1789991524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Accenture, Arhaus, AlkermesSeptember 21 (Reuters)-Wall Street futures advanced on Monday, led by AI stocks, as a 2% slide in oil prices pulled Treasury yields lower on sig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL6N45D0I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09311","LU1235294995.USD","LU1861217088.USD","LU0175139822.USD","MSTK","SG9999018865.SGD","PSCH","IE00BSNM7G36.USD","MSTR","SGXZ23171101.USD","LU0511384066.AUD","LU0545562505.USD","LU2211815571.USD","OWNB","ACN","LU1032466523.USD","LU0868494708.USD","BK4213","IE00BJJMRX11.SGD","BK4023","BPAY","BK4600","CONX","PSIL","MSTY.UK","LU0553294199.USD","LU1506573853.SGD","HOYY","IE00BFSS7M15.SGD","ALKS","LU1861559042.SGD","LU1228905540.USD","3SMI.UK","COIN","MEDX","BLCK","LU1003077747.HKD","IE000M9KFDE8.USD","HOOI","HOOW","LU1989772840.SGD","3LMI.UK","BK4554","HOOY","MSTC","FIAT","LU0323240290.USD","HOOZ","IBLC","LU0265550359.USD","COIO","SG9999018857.SGD","CONY","BK4108","LU1823568750.SGD","FDIG","BK4533","BK4561","LU0980610538.SGD","SGXZ31699556.SGD","COII","SMI3.UK","MSTW","LU1585245621.USD","COIA","BK4535","BK4134","BK4139","FBT","HOOC","LU0265550946.USD","LU0289960550.SGD","LU1366333091.USD","IBRN","APED","BK4551","LU1883839398.USD","MSII","BULL","LU0081259029.USD","HOOD","LU0868494617.USD","BK4585","LU0477156953.USD","09399","BK4127","07311","LU1989772923.USD","COIX","LU1430594728.SGD","LU0545039389.USD","REXC","LU2133065610.SGD","BK4168","MTYY","IMST","WBD","COIG","SG9999014880.SGD","IE00B7KXQ091.USD","IE00BJJMRY28.SGD","BK4588","BK4566","MSTY","SG9999014914.USD","SMST","CONL","LU1116320901.HKD","BK4534","CRPT","09711","CRMU","LU0149725797.USD","BULG","07399","COYY","CONI","BK4516","BK4539","PSKY","HK0000819398.USD","BK4598","LU0289961442.SGD","LU0289739343.SGD","GRML","07711","LU0157215616.USD","MSTP","LU0738911758.USD","LMI3.UK","BK4596","LU1228905037.USD","WNTR","LU1894683264.USD","CRMX","HOII","09799","BK4125","HOOX","IE00BFSS8Q28.SGD","GLND","IAI","IE0004445015.USD","LU0942090050.USD","MSDD","LU0323239441.USD","MST","MSST","SG9999014898.SGD","LU0130517989.USD","MSOO","BITQ","MSTX","SG9999004303.SGD","HOOG","LU1861558580.USD","SG9999017495.SGD","LU2247934214.USD","LU1116320737.USD","LU2360107671.USD","HODU","IE00BHPRN162.USD","MSTZ","ROBN","COIW","LU1861220207.SGD","SG9999014906.USD","BK4581","BULU","BK4178","LU0130102774.USD","BKCH","LU1894683348.USD","LU2381873111.SGD","LU1046421795.USD","BK4547","ARHS","BK4112","07799","DAPP","ICOI","LU0949170772.SGD","MSTU","LU2596442595.SGD","BK4595","LU1201861249.SGD","LU0661504455.SGD","CUE","LU0342679015.USD","LU0648001328.SGD","CRML","FINX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163577","title":"Alkermes jumps 8% to $46.99 after Phase I adult ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163577?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:50","pubTimestamp":1789991414,"startTime":"0","endTime":"0","summary":"07:46 EDT Alkermes (ALKS) jumps 8% to $46.99 after Phase I adult ADHD data Published first on TheFly – the ultimate source for real-time, market-mo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","ALKS","PSIL","IBRN","ABVC","BK4139","MEDX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150485","title":"Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150485?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:07","pubTimestamp":1789988867,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","ALKS","IBRN","FBT","PSCH","MEDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916887","title":"Alkermes announces Phase 1b results of ALKS 7290 in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916887?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:05","pubTimestamp":1789988737,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4139","PSIL","ABVC","PSCH","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669415062","title":"Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669415062","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669415062?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988517,"startTime":"0","endTime":"0","summary":"Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHDAlkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD; results have already been pre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2WW99h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","MEDX","BK4139","IBRN","PSIL","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}